Boston Harbor Angels Bet on New Frontier in Neuroscience
Boston Harbor Angels has invested in two neuroscience startups targeting stroke, TBI and Parkinson’s Disease, leading a $1.3M angel seed round in Astrocyte Pharmaceuticals and members investing in Neuraly.
Astrocyte Pharmaceuticals Inc. is a privately held drug development company dedicated to accelerating the recovery and well-being of brain injury patients. The company is committed to proving the neuroprotective benefits of selective astrocyte activation, and advancing breakthrough therapeutic agents for treating brain injury resulting from stroke, TBI, concussion, and neurodegenerative disorders such as Alzheimer’s Disease.
NLY001, a drug created by Neuraly, is a potential first in class disease modifying drug for Parkinson’s Disease.
About Boston Harbor Angels
Boston Harbor Angels, like a lighthouse, helps entrepreneurs navigate and grow their start-up businesses through the treacherous waters of an increasingly competitive environment in our global economy. Boston Harbor Angels is a group of proven business leaders interested in investing a portion of our assets in high-growth, early-stage companies. Since 2004 we have made investments in companies in medical devices, IT, consumer products, business products, specialty materials, Internet, aviation, etc. We believe we contribute more than money to the companies we fund and welcome the opportunity to work with entrepreneurs who are open to taking advice, yet have the smarts and determination to make their company successful.